Crossject is revolutionizing needle free injection


Crossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®. The prefilled, single-use device propels the medicine through the skin in less than a tenth of a second. Crossject currently has eight solutions in advanced stages of development, seven of which are for emergency situations.  

Zeneo illustration


Our news

Image de l'actualité

Bio-Europe Spring 2022

Résumé de l'actualité

Crossject wil be attending virtually at Bio-Europe Spring from March 28 to 31

Image de l'actualité

DCAT Week: March 21-24 in NY

Résumé de l'actualité

Olivier Giré, COO Specialty Pharma and Don Zinn, VP US Business, will be attending


Financial news: Agreement with BARDA on ZENEO® Midazolam

Sommaire ou résumé
  • BARDA places a firm order of $60m to CROSSJECT for initial procurement of ZENEO® Midazolam into the U.S.